Geode Capital Management LLC Purchases 1,138 Shares of XOMA Co. (NASDAQ:XOMA)

Geode Capital Management LLC lifted its position in shares of XOMA Co. (NASDAQ:XOMA) by 0.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 182,741 shares of the biotechnology company’s stock after buying an additional 1,138 shares during the period. Geode Capital Management LLC owned about 1.55% of XOMA worth $4,840,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of XOMA. BNP Paribas Financial Markets grew its stake in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. Rhumbline Advisers boosted its holdings in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the last quarter. Barclays PLC grew its position in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Ellsworth Advisors LLC acquired a new stake in XOMA in the 3rd quarter valued at $516,000. Finally, Bank of New York Mellon Corp lifted its position in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after buying an additional 1,968 shares in the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Insider Buying and Selling

In related news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the sale, the chief executive officer now owns 34,979 shares in the company, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on XOMA. HC Wainwright reaffirmed a “buy” rating and issued a $123.00 target price on shares of XOMA in a research report on Friday, December 13th. StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research report on Friday, December 27th.

XOMA Stock Up 3.2 %

XOMA stock opened at $26.82 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company’s 50-day moving average is $29.49 and its 200-day moving average is $27.90. The firm has a market capitalization of $316.02 million, a PE ratio of -7.71 and a beta of 0.88. XOMA Co. has a fifty-two week low of $18.57 and a fifty-two week high of $35.00.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.